June 2023
Volume 64, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2023
Depletion of memory Th17 cells ameliorates experimental chronic autoimmune uveitis
Author Affiliations & Notes
  • Qiurong Zhu
    Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Reza Dana
    Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Yihe Chen
    Department of Ophthalmology, Harvard Medical School, Schepens Eye Research Institute of Massachusetts Eye and Ear, Boston, Massachusetts, United States
  • Footnotes
    Commercial Relationships   Qiurong Zhu None; Reza Dana MEE, Code P (Patent); Yihe Chen MEE, Code P (Patent)
  • Footnotes
    Support  NIH EY031781 (Y.C.) and NIH P30EY003790 (Massachusetts Eye and Ear)
Investigative Ophthalmology & Visual Science June 2023, Vol.64, 4376. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Qiurong Zhu, Reza Dana, Yihe Chen; Depletion of memory Th17 cells ameliorates experimental chronic autoimmune uveitis. Invest. Ophthalmol. Vis. Sci. 2023;64(8):4376.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : Our previous work demonstrates that memory T cells mediate the retinopathy in a murine model of chronic autoimmune uveitis (CAU), and IL-7 is a critical surviving factor for memory Th17 cells. Herein, we aim to investigate the effect of blocking IL-7 in modulating clinical disease and memory Th17 cells in CAU.

Methods : CAU was induced in wild-type C57BL/6J mice by immunization with interphotoreceptor retinoid-binding protein (IRBP) peptides emulsified in complete Freund’s adjuvant (CFA), along with Bordetella pertussis toxin injection. The establishment of CAU was confirmed by digital fundus imaging at week 12. CAU mice then received intraperitoneal injections of 100μg anti-IL-7 antibody (Ab) or the control IgG every other day for 2 weeks for total of 8 injections. The clinical disease was assessed weekly by fundoscopy. After a 4-week follow-up, mice were euthanized, and ocular and lymphoid tissues were collected and analyzed for memory Th17 response by staining CD3, CD4, CD44, and IL-17 using flow cytometry.

Results : At the end of the 2-week treatment, CAU mice receiving the anti-IL-7 Ab showed a significantly reduced score of retinal vessel cuffing (2.8±0.6) compared to pre-treatment (4.6±1.0, p = 0.04), and this effect persisted until week 4 (1.2±0.4, p = 0.006), accompanied with significantly reduced retinal tissue infiltrates observed on fundus imaging (score of 1.8±0.5 vs. pre-treatment of 3.3±0.3, p = 0.02). In contrast, those treated with the control IgG did not show any significant clinical changes during the 4-week period. The cumulative response rates at week 4 were 67% for the anti-IL-7 Ab group and 0 for the control group (hazard ratio: 7.60, 95% CI: 0.98 – 58.88, p = 0.05). Flow cytometric analysis demonstrated that the anti-IL-7 Ab treatment led to a nearly complete depletion of T cells infiltrated in the retinal tissues in CAU, as well as an effective reduction of memory Th17 cells in the eye-draining lymph nodes compared to the control treatment (0.35±0.09% vs. 0.95±0.09%, p = 0.05).

Conclusions : Our data suggest that the depletion of memory Th17 cells by blocking IL-7 is a promising therapeutic strategy for chronic uveitis.

This abstract was presented at the 2023 ARVO Annual Meeting, held in New Orleans, LA, April 23-27, 2023.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×